MicroQuin was awarded a $250k grant from the Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) managed by the office of Congressionally Directed Medical Research Programs.

MicroQuin Announces Preclincial Collaboration with NIAID to Evaluate MicroQuin Therapeutics for the treatment of viral infections.

MicroQuin's experiments performed aboard the International Space Station have implications for earthbound biopharma development.

MicroQuin received investments from Tellus Bioventures. Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

South Summit is the leading innovation platform bringing together the most innovative startups regardless their industry, development stage and country.

MicroQuin's protein study to be conducted on the ISS was launched on 7/25 aboard SpaceX CRS-18. Read more on NASA's press releases here and here, 

A glimpse into the journey that Dr. Robinson has been on to drive our technology to its current stage. 

MicroQuin has been accepted into the highly competitive Lab Central.  We intend to continue our ground breaking research at this facility and strive to make significant advances in delivering first-in-class treatments for breast cancer.  Watch this space!

MicroQuin wins TWO grants from CASIS/BOEING under this year’s “Technology in Space” program. For the first time CASIS funded 2 projects from one company as part of its MassChallenge competition. These studies will be performed on the ISS and the data will have considerable impact on creating new scientific approaches to battling cancer.

MicroQuin was invited to showcase our high impact and transformational technology at Health Pioneers 2018.  The conference brings together decision-makers and innovators from the pharma, biotech, insurance and public health sectors to explore new ways to collaborate and pioneer. 

Health Hub Vienna is an acceleration program is managed by INiTS, Vienna’s high-tech incubator with an over 15-year track record of successfully developing start-ups in the life sciences.

The 26 finalists were selected among the 128 early-stage ventures at MassChallenge Boston’s acceleration program in May. The selected companies will move into the final judging round of the MassChallenge Awards, where they’ll compete for shares of $1.5 million in equity-free prizes.